Status:
RECRUITING
Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid
Lead Sponsor:
Egymedicalpedia
Collaborating Sponsors:
Aswan University
Conditions:
Refractory Melasma
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
Melasma is a common acquired disorder of hyperpigmentaion caused by increased melanin production by melanocytes. Melasma is a name derived from the Greek word melas meaning black.It is characterized ...
Detailed Description
Melasma is more common in people with dark complexions and Fitzpatrick skin types III IV.Depending on ethnicity and region, melasma prevalence might vary from 8.8% to 40%. The cause of melasma is stil...
Eligibility Criteria
Inclusion
- \- Patients of both sexes with melasma.
Exclusion
- Pregnancy
- Lactation
- Administration of oral contraceptive pills or any phototoxic drug within 1 month prior to study
- Patients with a history of thrombosis, abnormal bleeding profile, known hypersensitivity to TA or HQ, and endocrinal disease.
Key Trial Info
Start Date :
June 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 10 2025
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT06522984
Start Date
June 1 2024
End Date
June 10 2025
Last Update
July 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aswan University hospitals
Aswān, Egypt